<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37436162</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>Vemurafenib Inhibits Acute and Chronic Enterovirus Infection by Affecting Cellular Kinase Phosphatidylinositol 4-Kinase Type IIIβ.</ArticleTitle><Pagination><StartPage>e0055223</StartPage><MedlinePgn>e0055223</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00552-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.00552-23</ELocationID><Abstract><AbstractText>Enteroviruses are one of the most abundant viruses causing mild to serious acute infections in humans and also contributing to chronic diseases like type 1 diabetes. Presently, there are no approved antiviral drugs against enteroviruses. Here, we studied the potency of vemurafenib, an FDA-approved RAF kinase inhibitor for treating BRAF<sup>V600E</sup> mutant-related melanoma, as an antiviral against enteroviruses. We showed that vemurafenib prevented enterovirus translation and replication at low micromolar dosage in an RAF/MEK/ERK-independent manner. Vemurafenib was effective against group A, B, and C enteroviruses, as well as rhinovirus, but not parechovirus or more remote viruses such as Semliki Forest virus, adenovirus, and respiratory syncytial virus. The inhibitory effect was related to a cellular phosphatidylinositol 4-kinase type IIIβ (PI4KB), which has been shown to be important in the formation of enteroviral replication organelles. Vemurafenib prevented infection efficiently in acute cell models, eradicated infection in a chronic cell model, and lowered virus amounts in pancreas and heart in an acute mouse model. Altogether, instead of acting through the RAF/MEK/ERK pathway, vemurafenib affects the cellular PI4KB and, hence, enterovirus replication, opening new possibilities to evaluate further the potential of vemurafenib as a repurposed drug in clinical care. <b>IMPORTANCE</b> Despite the prevalence and medical threat of enteroviruses, presently, there are no antivirals against them. Here, we show that vemurafenib, an FDA-approved RAF kinase inhibitor for treating BRAF<sup>V600E</sup> mutant-related melanoma, prevents enterovirus translation and replication. Vemurafenib shows efficacy against group A, B, and C enteroviruses, as well as rhinovirus, but not parechovirus or more remote viruses such as Semliki Forest virus, adenovirus, and respiratory syncytial virus. The inhibitory effect acts through cellular phosphatidylinositol 4-kinase type IIIβ (PI4KB), which has been shown to be important in the formation of enteroviral replication organelles. Vemurafenib prevents infection efficiently in acute cell models, eradicates infection in a chronic cell model, and lowers virus amounts in pancreas and heart in an acute mouse model. Our findings open new possibilities to develop drugs against enteroviruses and give hope for repurposing vemurafenib as an antiviral drug against enteroviruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laajala</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwaagstra</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Virology, Division of Infectious Diseases &amp; Immunology, Department of Biomolecular Health Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martikainen</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nekoua</LastName><ForeName>Magloire Pandoua</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benkahla</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sane</LastName><ForeName>Famara</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gervais</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campagnola</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honkimaa</LastName><ForeName>Anni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Virology, Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sioofy-Khojine</LastName><ForeName>Amir-Babak</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Virology, Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyöty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology, Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ojha</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7876-4607</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailliot</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balistreri</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3585-559X</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Queensland Brain Institute, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peersen</LastName><ForeName>Olve</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6208-2660</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry &amp; Molecular Biology, Colorado State University, Fort Collins, Colorado, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hober</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie ULR3610, Université de Lille, CHU Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Kuppeveld</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Section of Virology, Division of Infectious Diseases &amp; Immunology, Department of Biomolecular Health Sciences, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marjomäki</LastName><ForeName>Varpu</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4592-5926</Identifier><AffiliationInfo><Affiliation>Department of Biological and Environmental Science/Nanoscience Center, University of Jyväskylä, Jyväskylä, Finland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI059130</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AI059130</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>207SMY3FQT</RegistryNumber><NameOfSubstance UI="D000077484">Vemurafenib</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.67</RegistryNumber><NameOfSubstance UI="D019870">1-Phosphatidylinositol 4-Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D048493">Proto-Oncogene Proteins B-raf</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.12.2</RegistryNumber><NameOfSubstance UI="D020929">Mitogen-Activated Protein Kinase Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077484" MajorTopicYN="N">Vemurafenib</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019870" MajorTopicYN="N">1-Phosphatidylinositol 4-Kinase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D048493" MajorTopicYN="N">Proto-Oncogene Proteins B-raf</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="Y">Melanoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020929" MajorTopicYN="N">Mitogen-Activated Protein Kinase Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute infection</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">chronic infection</Keyword><Keyword MajorTopicYN="N">drug repurposing</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword></KeywordList><CoiStatement>The authors declare a conflict of interest. H.Hy is a minor shareholder and member of the board of Vactech Ltd, which develops vaccines against picornaviruses. No other potential conflicts of interest relevant to this article were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>10</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37436162</ArticleId><ArticleId IdType="pmc">PMC10433971</ArticleId><ArticleId IdType="doi">10.1128/spectrum.00552-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tapparel C, Siegrist F, Petty TJ, Kaiser L. 2013. Picornavirus and enterovirus diversity with associated human diseases. Infect Genet Evol 14:282–293. doi:10.1016/j.meegid.2012.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2012.10.016</ArticleId><ArticleId IdType="pubmed">23201849</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M, Klingel K. 2009. Role of enteroviruses in the pathogenesis of type 1 diabetes. Diabetologia 52:995–996. doi:10.1007/s00125-009-1332-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-009-1332-9</ArticleId><ArticleId IdType="pubmed">19322560</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Honkanen H, Pakkanen O, Oikarinen S, Hankaniemi MM, Huhtala H, Ruokoranta T, Lecouturier V, André P, Harju R, Virtanen SM, Lehtonen J, Almond JW, Simell T, Simell O, Ilonen J, Veijola R, Knip M, Hyöty H. 2014. Coxsackievirus b1 is associated with induction of β-cell autoimmunity that portends type 1 diabetes. Diabetes 63:446–455. doi:10.2337/db13-0619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db13-0619</ArticleId><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekoua MP, Alidjinou EK, Hober D. 2022. Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol 18:503–516. doi:10.1038/s41574-022-00688-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-022-00688-1</ArticleId><ArticleId IdType="pmc">PMC9157043</ArticleId><ArticleId IdType="pubmed">35650334</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. 2017. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res 6:4–14. doi:10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov GA, Van Kuppeveld FJ. 2012. (+)RNA viruses rewire cellular pathways to build replication organelles. Curr Opin Virol 2:740–747. doi:10.1016/j.coviro.2012.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2012.09.006</ArticleId><ArticleId IdType="pmc">PMC7102821</ArticleId><ArticleId IdType="pubmed">23036609</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul D. 2013. Architecture and biogenesis of plus-strand RNA virus replication factories. World J Virol 2:32–48. doi:10.5501/wjv.v2.i2.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v2.i2.32</ArticleId><ArticleId IdType="pmc">PMC3785047</ArticleId><ArticleId IdType="pubmed">24175228</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. 2016. Mechanism of poliovirus resistance to host phosphatidylinositol-4 kinase III β inhibitor. ACS Infect Dis 2:140–148. doi:10.1021/acsinfecdis.5b00122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.5b00122</ArticleId><ArticleId IdType="pubmed">27624965</ArticleId></ArticleIdList></Reference><Reference><Citation>Melia CE, van der Schaar HM, Lyoo H, Limpens RWAL, Feng Q, Wahedi M, Overheul GJ, van Rij RP, Snijder EJ, Koster AJ, Bárcena M, van Kuppeveld FJM. 2017. Escaping host factor PI4KB inhibition: enterovirus genomic RNA replication in the absence of replication organelles. Cell Rep 21:587–599. doi:10.1016/j.celrep.2017.09.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2017.09.068</ArticleId><ArticleId IdType="pmc">PMC5656745</ArticleId><ArticleId IdType="pubmed">29045829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, Pau C, van der Schaar H, Kaushik-Basu N, Balla T, Cameron CE, Ehrenfeld E, van Kuppeveld FJM, Altan-Bonnet N. 2010. Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell 141:799–811. doi:10.1016/j.cell.2010.03.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.03.050</ArticleId><ArticleId IdType="pmc">PMC2982146</ArticleId><ArticleId IdType="pubmed">20510927</ArticleId></ArticleIdList></Reference><Reference><Citation>Greninger AL, Knudsen GM, Betegon M, Burlingame AL, DeRisi JL. 2012. The 3A protein from multiple picornaviruses utilizes the Golgi adaptor protein ACBD3 to recruit PI4KIIIβ. J Virol 86:3605–3616. doi:10.1128/JVI.06778-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.06778-11</ArticleId><ArticleId IdType="pmc">PMC3302542</ArticleId><ArticleId IdType="pubmed">22258260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA. 2011. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516. doi:10.1056/NEJMoa1103782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1103782</ArticleId><ArticleId IdType="pmc">PMC3549296</ArticleId><ArticleId IdType="pubmed">21639808</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KYJ, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D’Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596–599. doi:10.1038/nature09454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09454</ArticleId><ArticleId IdType="pmc">PMC2948082</ArticleId><ArticleId IdType="pubmed">20823850</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh YT, Deng J, Yue P, Sun SY. 2016. Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells. Sci Rep 6:26803. doi:10.1038/srep26803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26803</ArticleId><ArticleId IdType="pmc">PMC4879700</ArticleId><ArticleId IdType="pubmed">27222248</ArticleId></ArticleIdList></Reference><Reference><Citation>Myllynen M, Kazmertsuk A, Marjomäki V. 2016. A novel open and infectious form of echovirus 1. J Virol 90:6759–6770. doi:10.1128/JVI.00342-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00342-16</ArticleId><ArticleId IdType="pmc">PMC4944302</ArticleId><ArticleId IdType="pubmed">27194757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruokolainen V, Laajala M, Marjomäki V. 2020. Real-time fluorescence measurement of enterovirus uncoating. Bio Protoc 10:e3582. doi:10.21769/BioProtoc.3582.</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/BioProtoc.3582</ArticleId><ArticleId IdType="pmc">PMC7842371</ArticleId><ArticleId IdType="pubmed">33659552</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruokolainen V, Domanska A, Laajala M, Pelliccia M, Butcher SJ, Marjomäki V. 2019. Extracellular albumin and endosomal ions prime enterovirus particles for uncoating that can be prevented by fatty acid saturation. J Virol 93:e00599-19. doi:10.1128/JVI.00599-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00599-19</ArticleId><ArticleId IdType="pmc">PMC6694817</ArticleId><ArticleId IdType="pubmed">31189702</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong P, Campagnola G, Peersen OB. 2009. A quantitative stopped-flow fluorescence assay for measuring polymerase elongation rates. Anal Biochem 391:45–55. doi:10.1016/j.ab.2009.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2009.04.035</ArticleId><ArticleId IdType="pmc">PMC2713312</ArticleId><ArticleId IdType="pubmed">19406094</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Schaar HM, Van Der Linden L, Lanke KHW, Strating JRPM, Pürstinger G, De Vries E, De Haan CAM, Neyts J, Van Kuppeveld FJM. 2012. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. Cell Res 22:1576–1592. doi:10.1038/cr.2012.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2012.129</ArticleId><ArticleId IdType="pmc">PMC3494396</ArticleId><ArticleId IdType="pubmed">22945356</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating JRPM, van der Linden L, Albulescu L, Bigay J, Arita M, Delang L, Leyssen P, van der Schaar HM, Lanke KHW, Thibaut HJ, Ulferts R, Drin G, Schlinck N, Wubbolts RW, Sever N, Head SA, Liu JO, Beachy PA, DeMatteis MA, Shair MD, Olkkonen VM, Neyts J, van Kuppeveld FJM. 2015. Itraconazole inhibits enterovirus replication by targeting the oxysterol-binding protein. Cell Rep 10:600–615. doi:10.1016/j.celrep.2014.12.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.054</ArticleId><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridgway ND, Dawson PA, Ho YK, Brown MS, Goldstein JL. 1992. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. J Cell Biology 116:307–319. doi:10.1083/jcb.116.2.307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.116.2.307</ArticleId><ArticleId IdType="pmc">PMC2289278</ArticleId><ArticleId IdType="pubmed">1730758</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2013. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds. J Virol 87:4252–4260. doi:10.1128/JVI.03546-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03546-12</ArticleId><ArticleId IdType="pmc">PMC3624399</ArticleId><ArticleId IdType="pubmed">23365445</ArticleId></ArticleIdList></Reference><Reference><Citation>Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW, Matthews DA, Patick AK. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 49:619–626. doi:10.1128/AAC.49.2.619-626.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.2.619-626.2005</ArticleId><ArticleId IdType="pmc">PMC547258</ArticleId><ArticleId IdType="pubmed">15673742</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ, Zalman LS, Burns-Naas LA, Tran JQ. 2005. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 49:2267–2275. doi:10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 43:2444–2450. doi:10.1128/AAC.43.10.2444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.43.10.2444</ArticleId><ArticleId IdType="pmc">PMC89498</ArticleId><ArticleId IdType="pubmed">10508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser L, Crump CE, Hayden FG. 2000. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res 47:215–220. doi:10.1016/s0166-3542(00)00106-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0166-3542(00)00106-6</ArticleId><ArticleId IdType="pubmed">10974374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ, Zalman LS. 2003. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 47:3907–3916. doi:10.1128/AAC.47.12.3907-3916.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.12.3907-3916.2003</ArticleId><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, Sznol M. 2010. PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells. Pigment Cell Melanoma Res 23:190–200. doi:10.1111/j.1755-148X.2010.00685.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-148X.2010.00685.x</ArticleId><ArticleId IdType="pmc">PMC2848976</ArticleId><ArticleId IdType="pubmed">20149136</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzberg M, Boergeling Y, Schräder T, Ludwig S, Ehrhardt C. 2017. Vemurafenib limits influenza A virus propagation by targeting multiple signaling pathways. Front Microbiol 8:2426. doi:10.3389/fmicb.2017.02426.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02426</ArticleId><ArticleId IdType="pmc">PMC5735105</ArticleId><ArticleId IdType="pubmed">29312159</ArticleId></ArticleIdList></Reference><Reference><Citation>Soonsawad P, Paavolainen L, Upla P, Weerachatyanukul W, Rintanen N, Espinoza J, McNerney G, Marjomäki V, Cheng RH. 2014. Permeability changes of integrin-containing multivesicular structures triggered by picornavirus entry. PLoS One 9:e108948. doi:10.1371/journal.pone.0108948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0108948</ArticleId><ArticleId IdType="pmc">PMC4191987</ArticleId><ArticleId IdType="pubmed">25299706</ArticleId></ArticleIdList></Reference><Reference><Citation>Upla P, Marjomäki V, Nissinen L, Nylund C, Waris M, Hyypiä T, Heino J. 2008. Calpain 1 and 2 are required for RNA replication of echovirus 1. J Virol 82:1581–1590. doi:10.1128/JVI.01375-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01375-07</ArticleId><ArticleId IdType="pmc">PMC2224425</ArticleId><ArticleId IdType="pubmed">18032503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Chik KK-H, Chan JF-W, Cai J-P, Cao H, Tsang JO-L, Zou Z, Hung Y-P, Tang K, Jia L, Luo C, Yin F, Ye Z-W, Chu H, Yeung M-L, Yuan S. 2022. Vemurafenib inhibits enterovirus A71 genome replication and virus assembly. Pharmaceuticals 15:1067. doi:10.3390/ph15091067.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15091067</ArticleId><ArticleId IdType="pmc">PMC9500672</ArticleId><ArticleId IdType="pubmed">36145288</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar HM, Leyssen P, Thibaut HJ, de Palma A, van der Linden L, Lanke KHW, Lacroix C, Verbeken E, Conrath K, MacLeod AM, Mitchell DR, Palmer NJ, van de Poël H, Andrews M, Neyts J, van Kuppeveld FJM. 2013. A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ. Antimicrob Agents Chemother 57:4971–4981. doi:10.1128/AAC.01175-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01175-13</ArticleId><ArticleId IdType="pmc">PMC3811463</ArticleId><ArticleId IdType="pubmed">23896472</ArticleId></ArticleIdList></Reference><Reference><Citation>Spickler C, Lippens J, Laberge M-K, Desmeules S, Bellavance É, Garneau M, Guo T, Hucke O, Leyssen P, Neyts J, Vaillancourt FH, Décor A, O'Meara J, Franti M, Gauthier A. 2013. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. Antimicrob Agents Chemother 57:3358–3368. doi:10.1128/AAC.00303-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00303-13</ArticleId><ArticleId IdType="pmc">PMC3697394</ArticleId><ArticleId IdType="pubmed">23650168</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H. 2011. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity. J Virol 85:2364–2372. doi:10.1128/JVI.02249-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02249-10</ArticleId><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogerus C, Egger D, Samuilova O, Hyypiä T, Bienz K. 2003. Replication complex of human parechovirus 1. J Virol 77:8512–8523. doi:10.1128/JVI.77.15.8512-8523.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.15.8512-8523.2003</ArticleId><ArticleId IdType="pmc">PMC165257</ArticleId><ArticleId IdType="pubmed">12857920</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazina EV, Mackenzie JM, Gorrell RJ, Anderson DA. 2002. Differential requirements for COPI coats in formation of replication complexes among three genera of Picornaviridae. J Virol 76:11113–11122. doi:10.1128/JVI.76.21.11113-11122.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.21.11113-11122.2002</ArticleId><ArticleId IdType="pmc">PMC136594</ArticleId><ArticleId IdType="pubmed">12368353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyoo H, van der Schaar HM, Dorobantu CM, Rabouw HH, Strating JRPM, van Kuppeveld FJM. 2019. ACBD3 is an essential pan-enterovirus host factor that mediates the interaction between viral 3A protein and cellular protein PI4KB. mBio 10:e02742-18. doi:10.1128/mBio.02742-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.02742-18</ArticleId><ArticleId IdType="pmc">PMC6372799</ArticleId><ArticleId IdType="pubmed">30755512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasvari Z, Nagy PD. 2010. Making of viral replication organelles by remodeling interior membranes. Viruses 2:2436–2442. doi:10.3390/v2112436.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v2112436</ArticleId><ArticleId IdType="pmc">PMC3185585</ArticleId><ArticleId IdType="pubmed">21994625</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M. 2014. Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure. Microbiol Immunol 58:239–256. doi:10.1111/1348-0421.12144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1348-0421.12144</ArticleId><ArticleId IdType="pubmed">24527995</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Bigay J. 2019. Poliovirus evolution toward independence from the phosphatidylinositol-4 kinase III β/oxysterol-binding protein family I pathway. ACS Infect Dis 5:962–973. doi:10.1021/acsinfecdis.9b00038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00038</ArticleId><ArticleId IdType="pubmed">30919621</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesmin B, Bigay J, Moser Von Filseck J, Lacas-Gervais S, Drin G, Antonny B. 2013. XA four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi Tether OSBP. Cell 155:830–843. doi:10.1016/j.cell.2013.09.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.09.056</ArticleId><ArticleId IdType="pubmed">24209621</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMarche MJ, Borawski J, Bose A, Capacci-Daniel C, Colvin R, Dennehy M, Ding J, Dobler M, Drumm J, Gaither LA, Gao J, Jiang X, Lin K, McKeever U, Puyang X, Raman P, Thohan S, Tommasi R, Wagner K, Xiong X, Zabawa T, Zhu S, Wiedmann B. 2012. Anti-hepatitis C virus activity and toxicity of type III phosphatidylinositol-4-kinase beta inhibitors. Antimicrob Agents Chemother 56:5149–5156. doi:10.1128/AAC.00946-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00946-12</ArticleId><ArticleId IdType="pmc">PMC3457382</ArticleId><ArticleId IdType="pubmed">22825118</ArticleId></ArticleIdList></Reference><Reference><Citation>Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W, Donica M, Makrutzki M, Blank C. 2019. An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. Eur J Cancer 107:175–185. doi:10.1016/j.ejca.2018.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejca.2018.11.018</ArticleId><ArticleId IdType="pubmed">30580112</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaika A, Crozier JA, Joseph RW. 2014. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther 2014:775–787. doi:10.2147/DDDT.S31143.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S31143</ArticleId><ArticleId IdType="pmc">PMC4064951</ArticleId><ArticleId IdType="pubmed">24966667</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhaveri KD, Sakhiya V, Fishbane S. 2015. Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol 1:1133. doi:10.1001/jamaoncol.2015.1713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaoncol.2015.1713</ArticleId><ArticleId IdType="pubmed">26182194</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek J, Cianciolo RE, Baker SD, Sparreboom A, Jhaveri KD, Susztak K, Bajwa A, Pabla NS. 2021. Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. Kidney Int 100:1214–1226. doi:10.1016/j.kint.2021.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.08.022</ArticleId><ArticleId IdType="pmc">PMC8608726</ArticleId><ArticleId IdType="pubmed">34534550</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, Gauvain K, Leary S, Dhall G, Aboian M, Robinson G, Long-Boyle J, Wang H, Molinaro AM, Mueller S, Prados M. 2020. Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget 11:1942–1952. doi:10.18632/oncotarget.27600.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.27600</ArticleId><ArticleId IdType="pmc">PMC7260122</ArticleId><ArticleId IdType="pubmed">32523649</ArticleId></ArticleIdList></Reference><Reference><Citation>Tardieu M, Néron A, Duvert-Lehembre S, Amine Larabi I, Barkaoui M, Emile JF, Seigneurin A, Boralevi F, Donadieu J. 2021. Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis. Pediatr Blood Cancer 68:e29140. doi:10.1002/pbc.29140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.29140</ArticleId><ArticleId IdType="pubmed">34109735</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspari S, Di Ruscio V, Stocchi F, Carta R, Becilli M, De Ioris MA. 2021. Case report: early association of vemurafenib to standard chemotherapy in multisystem Langerhans cell histiocytosis in a newborn: taking a chance for a better outcome? Front Oncol 11:794498. doi:10.3389/fonc.2021.794498.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.794498</ArticleId><ArticleId IdType="pmc">PMC8710608</ArticleId><ArticleId IdType="pubmed">34966688</ArticleId></ArticleIdList></Reference><Reference><Citation>Petruzzellis G, Valentini D, Del Bufalo F, Ceglie G, Carai A, Colafati GS, Agolini E, Diomedi-Camassei F, Corsetti T, Alessi I, Mastronuzzi A, Locatelli F, Cacchione A. 2019. Vemurafenib treatment of pleomorphic xanthoastrocytoma in a child with down syndrome. Front Oncol 9:277. doi:10.3389/fonc.2019.00277.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00277</ArticleId><ArticleId IdType="pmc">PMC6474392</ArticleId><ArticleId IdType="pubmed">31032231</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A, Thibaut HJ, Spieser SAH, De Palma A, Koukni M, Rhoden E, Oberste S, Pürstinger G, Volny-Luraghi A, Martin J, Marchand A, Chaltin P, Neyts J, Leyssen P. 2014. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. Antiviral Res 110:1–9. doi:10.1016/j.antiviral.2014.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2014.07.003</ArticleId><ArticleId IdType="pubmed">25043639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Manganaro R, Zonsics B, Hurdiss DL, Zwaagstra M, Donselaar T, Welter NGE, Van Kleef RGDM, Lopez ML, Bevilacqua F, Raman T, Ferla S, Bassetto M, Neyts J, Strating JRPM, Westerink RHS, Brancale A, Van Kuppeveld FJM. 2020. Rational design of highly potent broadspectrum enterovirus inhibitors targeting the nonstructural protein 2C. PLoS Biol 18:e3000904. doi:10.1371/journal.pbio.3000904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000904</ArticleId><ArticleId IdType="pmc">PMC7673538</ArticleId><ArticleId IdType="pubmed">33156822</ArticleId></ArticleIdList></Reference><Reference><Citation>Delang L, Guerrero NS, Tas A, Quérat G, Pastorino B, Froeyen M, Dallmeier K, Jochmans D, Herdewijn P, Bello F, Snijder EJ, de Lamballerie X, Martina B, Neyts J, van Hemert MJ, Leyssen P. 2014. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69:2770–2784. doi:10.1093/jac/dku209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dku209</ArticleId><ArticleId IdType="pubmed">24951535</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Wakita T, Shimizu H. 2008. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J General Virology 89:2518–2530. doi:10.1099/vir.0.2008/002915-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.2008/002915-0</ArticleId><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden L, Wolthers K, van Kuppeveld F. 2015. Replication and inhibitors of enteroviruses and parechoviruses. Viruses 7:4529–4562. doi:10.3390/v7082832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7082832</ArticleId><ArticleId IdType="pmc">PMC4576193</ArticleId><ArticleId IdType="pubmed">26266417</ArticleId></ArticleIdList></Reference><Reference><Citation>Martín-Acebes MA, Blázquez AB, Jiménez de Oya N, Escribano-Romero E, Saiz JC. 2011. West Nile virus replication requires fatty acid synthesis but is independent on phosphatidylinositol-4-phosphate lipids. PLoS One 6:e24970. doi:10.1371/journal.pone.0024970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024970</ArticleId><ArticleId IdType="pmc">PMC3176790</ArticleId><ArticleId IdType="pubmed">21949814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine AB, Honkimaa A, Hyöty H. 2020. A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Diabet Med 37:1849–1853. doi:10.1111/dme.14175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.14175</ArticleId><ArticleId IdType="pubmed">31705692</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseligka ED, Sobo K, Stoppini L, Cagno V, Abdul F, Piuz I, Meylan P, Huang S, Constant S, Tapparel C. 2018. A VP1 mutation acquired during an enterovirus 71 disseminated infection confers heparan sulfate binding ability and modulates ex vivo tropism. PLoS Pathog 14:e1007190. doi:10.1371/journal.ppat.1007190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007190</ArticleId><ArticleId IdType="pmc">PMC6093697</ArticleId><ArticleId IdType="pubmed">30075025</ArticleId></ArticleIdList></Reference><Reference><Citation>Spuul P, Balistreri G, Kääriäinen L, Ahola T. 2010. Phosphatidylinositol 3-kinase-, actin-, and microtubule-dependent transport of Semliki Forest virus replication complexes from the plasma membrane to modified lysosomes. J Virol 84:7543–7557. doi:10.1128/JVI.00477-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00477-10</ArticleId><ArticleId IdType="pmc">PMC2897599</ArticleId><ArticleId IdType="pubmed">20484502</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelkmans L, Fava E, Grabner H, Hannus M, Habermann B, Krausz E, Zerial M. 2005. Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis. Nature 436:78–86. doi:10.1038/nature03571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03571</ArticleId><ArticleId IdType="pubmed">15889048</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzyzaniak MA, Zumstein MT, Gerez JA, Picotti P, Helenius A. 2013. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog 9:e1003309. doi:10.1371/journal.ppat.1003309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003309</ArticleId><ArticleId IdType="pmc">PMC3623752</ArticleId><ArticleId IdType="pubmed">23593008</ArticleId></ArticleIdList></Reference><Reference><Citation>Sane F, Caloone D, Gmyr V, Engelmann I, Belaich S, Kerr-Conte J, Pattou F, Desailloud R, Hober D. 2013. Coxsackievirus B4 can infect human pancreas ductal cells and persist in ductal-like cell cultures which results in inhibition of Pdx1 expression and disturbed formation of islet-like cell aggregates. Cell Mol Life Sci 70:4169–4180. doi:10.1007/s00018-013-1383-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-013-1383-4</ArticleId><ArticleId IdType="pmc">PMC11113870</ArticleId><ArticleId IdType="pubmed">23775130</ArticleId></ArticleIdList></Reference><Reference><Citation>Alidjinou EK, Engelmann I, Bossu J, Villenet C, Figeac M, Romond MB, Sané F, Hober D. 2017. Persistence of coxsackievirus B4 in pancreatic ductal-like cells results in cellular and viral changes. Virulence 8:1229–1244. doi:10.1080/21505594.2017.1284735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2017.1284735</ArticleId><ArticleId IdType="pmc">PMC5711397</ArticleId><ArticleId IdType="pubmed">28112573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekoua MP, Bertin A, Sane F, Gimeno JP, Fournier I, Salzet M, Engelmann I, Alidjinou EK, Hober D. 2021. Persistence of coxsackievirus b4 in pancreatic β cells disturbs insulin maturation, pattern of cellular proteins, and DNA methylation. Microorganisms 9:1125. doi:10.3390/microorganisms9061125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9061125</ArticleId><ArticleId IdType="pmc">PMC8224704</ArticleId><ArticleId IdType="pubmed">34067388</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomäki V, Pietiäinen V, Matilainen H, Upla P, Ivaska J, Nissinen L, Reunanen H, Huttunen P, Hyypiä T, Heino J. 2002. Internalization of echovirus 1 in caveolae. J Virol 76:1856–1865. doi:10.1128/JVI.76.4.1856-1865.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.4.1856-1865.2002</ArticleId><ArticleId IdType="pmc">PMC135881</ArticleId><ArticleId IdType="pubmed">11799180</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Svedin E, Kapell S, Hankaniemi MM, Larsson PG, Domsgen E, Stone VM, Määttä JAE, Hyöty H, Hytönen VP, Flodström-Tullberg M. 2018. New coxsackievirus 2Apro and 3Cpro protease antibodies for virus detection and discovery of pathogenic mechanisms. J Virol Methods 255:29–37. doi:10.1016/j.jviromet.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2018.02.001</ArticleId><ArticleId IdType="pubmed">29425680</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q, Langereis MA, Lork M, Nguyen M, Hato SV, Lanke K, Emdad L, Bhoopathi P, Fisher PB, Lloyd RE, van Kuppeveld FJM. 2014. Enterovirus 2A pro targets MDA5 and MAVS in infected cells. J Virol 88:3369–3378. doi:10.1128/JVI.02712-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02712-13</ArticleId><ArticleId IdType="pmc">PMC3957915</ArticleId><ArticleId IdType="pubmed">24390337</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins CL, Kempf BJ, Beaucourt S, Barton DJ, Peersen OB. 2020. Picornaviral polymerase domain exchanges reveal a modular basis for distinct biochemical activities of viral RNA-dependent RNA polymerases. J Biol Chem 295:10624–10637. doi:10.1074/jbc.RA120.013906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA120.013906</ArticleId><ArticleId IdType="pmc">PMC7397104</ArticleId><ArticleId IdType="pubmed">32493771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>